logo
Plus   Neg
Share
Email

Merck To Acquire Pandion Therapeutics - Quick Facts

Merck (MRK) has agreed to acquire Pandion Therapeutics, Inc. (PAND), a clinical-stage biotechnology company developing therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion.

Merck, through a unit, will initiate a tender offer to acquire all outstanding shares of Pandion. Upon the successful completion of the tender offer, Merck's acquisition unit will be merged into Pandion. The deal is expected to close in the first half of 2021.

PT101, the lead candidate of Pandion, is an engineered IL-2 mutein fused to a protein backbone designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases. PT101 had completed a phase 1a clinical trial, which achieved its primary objective of safety and tolerability.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna, Inc. announced that updated cases in its trial show its COVID-19 Vaccine (mRNA-1273) is greater than 90% effective against all cases of COVID-19, with around 6 months median follow-up post-dose 2. The new data from the Phase 3 COVE Study also shows that the vaccine is greater than 95% effective against severe cases of COVID-19. The U.S. Food and Drug Administration on Tuesday announced a temporarily halt on the usage of Johnson & Johnson's (JNJ) Covid-19 vaccine after six recipients developed a rare blood clotting disorder. "Right now, these adverse events appear to be extremely rare," the FDA said in a joint statement with... Best Buy is set to offer free doorstep e-waste collection for residents in St. Louis as part of its celebration of Earth Month. The electronics retailer will pilot the new program to pickup old electronic gadgets like phones, laptops, tablets as well as large TVs and appliances for recycling.
Follow RTT